Return to Listing

2 result(s) for VIDAZA

PI Name Protocol # Title
Emma Scott STUDY00015214 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Laura Newell STUDY00015619 A phase 1/2 study of Vadastuximab Talirine (SGN-CD33A) in combination with Azacitidine in patients with previously untreated international prognostic scoring system (IPSS) intermediate -2 or high-risk Myelodysplastic Syndrome (MDS).

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080